NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Jonas DE, Wines RCM, DelMonte M, et al. Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Apr.

Cover of Drug Class Review: Controller Medications for Asthma

Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].

Show details

Appendix HStrength of evidence

Table H-1. Strength of evidence for the comparative efficacy of inhaled corticosteroids

Table H-2. Strength of evidence for the comparative efficacy of leukotriene modifiers (LMs)

Table H-3. Strength of evidence for the comparative efficacy of LABAs

Table H-4. Strength of evidence for the comparative efficacy of omalizumab and placebo

Table H-5. Strength of evidence for the comparative efficacy of BUD/FM and FP/SM

Table H-6. Strength of evidence for for the comparative efficacy of BUD/FM for maintenance and as-needed relief (BUD/FM MART) and ICS/LABA with a Short-Acting Beta-Agonist (SABA) for relief

Table H-7. Strength of evidence for the comparative efficacy of ICSs and LTRAs

Table H-8. Strength of evidence for the comparative efficacy of ICSs and LABAs for monotherapy

Table H-9. Strength of evidence for the comparative efficacy of leukotriene modifiers and LABAs for monotherapy

Table H-10. Strength of evidence for the comparative efficacy of ICS + LABA and same dose ICS alone as first line therapy

Table H-11. Strength of evidence for the comparative efficacy of ICS + LABA compared with higher dose ICS

Table H-12. Strength of evidence for the comparative efficacy of addition of LABA to ICS compared with continuing same dose ICS

Table H-13. Strength of evidence for the comparative efficacy of ICS + LTRA and ICS

Table H-14. Strength of evidence for the comparative efficacy of LABA + ICS and LTRA

Table H-15. Strength of evidence for the comparative efficacy of LTRA + ICS and LABA + ICS

Table H-16. Strength of evidence for the comparative efficacy of ICS + LABA and LTRA + LABA

Table H-17. Strength of evidence for tolerability and frequency of adverse events of BUD/FM compared with FP/SM

Copyright © 2011 by Oregon Health & Science University.
Bookshelf ID: NBK56686
PubReader format: click here to try

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...